Dutch biotech firm, VectorY, has raised $138m to advance its antibody technology in the treatment of neurodegenerative diseases, particularly ALS. By targeting the misfolded protein TDP-43 with antibodies, VectorY’s drug therapy could potentially tackle an aggressive form of ALS that has previously proved difficult to treat. The funding will be used to push the lead programme, VTX-002, into clinical trials which are hoped to begin in early 2025.
News – Scroller Home Page – Kelly Benefits data breach compromised over half a million individuals – teiss
Summarize this content to a maximum of 60 words: News – Scroller Home Page – Kelly Benefits data breach compromised over half a million individuals teiss
